|
1
|
Park W, Chawla A and O'Reilly EM:
Pancreatic cancer: A review. JAMA. 326:851–862. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Versteijne E, Suker M, Groothuis K,
Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch
OR, Creemers GM, van Dam RM, et al: Preoperative chemoradiotherapy
versus immediate surgery for resectable and borderline resectable
pancreatic cancer: Results of the dutch randomized phase III
PREOPANC trial. J Clin Oncol. 38:1763–1773. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rojas LA, Sethna Z, Soares KC, Olcese C,
Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al:
Personalized RNA neoantigen vaccines stimulate T cells in
pancreatic cancer. Nature. 618:144–150. 2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
O'Reilly EM, Lee JW, Zalupski M, Capanu M,
Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, et al:
Randomized, multicenter, phase II trial of gemcitabine and
cisplatin with or without veliparib in patients with pancreas
adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol.
38:1378–1388. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lai E, Ziranu P, Spanu D, Dubois M, Pretta
A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, et al:
BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer.
125:1321–1332. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wattenberg MM, Asch D, Yu S, O'Dwyer PJ,
Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES and
Reiss KA: Platinum response characteristics of patients with
pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or
PALB2 mutation. Br J Cancer. 122:333–339. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825.
2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Reiss KA, Mick R, O'Hara MH, Teitelbaum U,
Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izgur N,
et al: Phase II study of maintenance rucaparib in patients with
platinum-sensitive advanced pancreatic cancer and a pathogenic
germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin
Oncol. 39:2497–2505. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Golan T, Hammel P, Reni M, Van Cutsem E,
Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Maintenance olaparib for germline BRCA-mutated metastatic
pancreatic cancer. N Engl J Med. 381:317–327. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Samstein RM, Krishna C, Ma X, Pei X, Lee
KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, et al:
Mutations in BRCA1 and BRCA2 differentially affect the tumor
microenvironment and response to checkpoint blockade immunotherapy.
Nat Cancer. 1:1188–1203. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Terrero G, Datta J, Dennison J, Sussman
DA, Lohse I, Merchant NB and Hosein PJ: Ipilimumab/nivolumab
therapy in patients with metastatic pancreatic or biliary cancer
with homologous recombination deficiency pathogenic germline
variants. JAMA Oncol. 8:1–3. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Huang H, Zhong P, Zhu X, Fu S, Li S, Peng
S, Liu Y, Lu Z and Chen L: Immunotherapy combined with
rh-endostatin improved clinical outcomes over immunotherapy plus
chemotherapy for second-line treatment of advanced NSCLC. Front
Oncol. 13(1137224)2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hack SP, Zhu AX and Wang Y: Augmenting
anticancer immunity through combined targeting of angiogenic and
PD-1/PD-L1 pathways: Challenges and opportunities. Front Immunol.
11(598877)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang Y, Wang B, Xiang L, Deng J, Xu B, He
P, Pu W, Wang H, Fan Y and Chen H: Case report: Anlotinib combined
with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX
chemotherapy in treatment of KRAS G12V mutated pancreatic ductal
adenocarcinoma with liver metastasis: A case and literature review.
Front Immunol. 13(1016647)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mafei K, Shengyuan X and Jieqiong S:
Pembrolizumab enhances the anti-pancreatic cancer activity of
anlotinib. Asian J Surg. 45:881–882. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ghaneh P, Kleeff J, Halloran CM, Raraty M,
Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, et al:
The Impact of positive resection margins on survival and recurrence
following resection and adjuvant chemotherapy for pancreatic ductal
adenocarcinoma. Ann Surg. 269:520–529. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Verbeke CS, Leitch D, Menon KV, McMahon
MJ, Guillou PJ and Anthoney A: Redefining the R1 resection in
pancreatic cancer. Br J Surg. 93:1232–1237. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982.PubMed/NCBI
|
|
20
|
NCCN Guidelines Panel Disclosures. NCCN
Clinical Practice Guidelines in Oncology-Pancreatic Adenocarcinoma
(Version 2.2023). [June 19, 2023]. https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients.
|
|
21
|
Middleton G, Silcocks P, Cox T, Valle J,
Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, et
al: Gemcitabine and capecitabine with or without telomerase peptide
vaccine GV1001 in patients with locally advanced or metastatic
pancreatic cancer (TeloVac): An open-label, randomised, phase 3
trial. Lancet Oncol. 15:829–840. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lellouche L, Palmieri LJ, Dermine S,
Brezault C, Chaussade S and Coriat R: Systemic therapy in
metastatic pancreatic adenocarcinoma: Current practice and
perspectives. Ther Adv Med Oncol.
13(17588359211018539)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Walsh CS: Two decades beyond BRCA1/2:
Homologous recombination, hereditary cancer risk and a target for
ovarian cancer therapy. Gynecol Oncol. 137:343–350. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Andrei AZ, Hall A, Smith AL, Bascuñana C,
Malina A, Connor A, Altinel-Omeroglu G, Huang S, Pelletier J,
Huntsman D, et al: Increased in vitro and in vivo sensitivity of
BRCA2-associated pancreatic cancer to the poly(ADP-ribose)
polymerase-1/2 inhibitor BMN 673. Cancer Lett. 364:8–16.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang Y, Park JYP, Pacis A, Denroche RE,
Jang GH, Zhang A, Cuggia A, Domecq C, Monlong J, Raitses-Gurevich
M, et al: A preclinical trial and molecularly annotated patient
cohort identify predictive biomarkers in homologous
recombination-deficient pancreatic cancer. Clin Cancer Res.
26:5462–5476. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
national cancer institute of canada clinical trials group. J Clin
Oncol. 25:1960–1966. 2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Van Cutsem E, van de Velde H, Karasek P,
Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype
C, Neumann H, et al: Phase III trial of gemcitabine plus tipifarnib
compared with gemcitabine plus placebo in advanced pancreatic
cancer. J Clin Oncol. 22:1430–1438. 2004.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Van Cutsem E, Vervenne WL, Bennouna J,
Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang
A, Cosaert J and Moore MJ: Phase III trial of bevacizumab in
combination with gemcitabine and erlotinib in patients with
metastatic pancreatic cancer. J Clin Oncol. 27:2231–2237.
2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kindler HL, Niedzwiecki D, Hollis D,
Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF,
O'Reilly E, Wozniak TF, et al: Gemcitabine plus bevacizumab
compared with gemcitabine plus placebo in patients with advanced
pancreatic cancer: Phase III trial of the cancer and leukemia group
B (CALGB 80303). J Clin Oncol. 28:3617–3622. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kindler HL, Ioka T, Richel DJ, Bennouna J,
Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S,
et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in
patients with advanced pancreatic adenocarcinoma: A double-blind
randomised phase 3 study. Lancet Oncol. 12:256–262. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gonçalves A, Gilabert M, François E, Dahan
L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X,
et al: BAYPAN study: A double-blind phase III randomized trial
comparing gemcitabine plus sorafenib and gemcitabine plus placebo
in patients with advanced pancreatic cancer. Ann Oncol.
23:2799–2805. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Rougier P, Riess H, Manges R, Karasek P,
Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L and
Philip PA: Randomised, placebo-controlled, double-blind,
parallel-group phase III study evaluating aflibercept in patients
receiving first-line treatment with gemcitabine for metastatic
pancreatic cancer. Eur J Cancer. 49:2633–2642. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yamaue H, Tsunoda T, Tani M, Miyazawa M,
Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, et al:
Randomized phase II/III clinical trial of elpamotide for patients
with advanced pancreatic cancer: PEGASUS-PC study. Cancer Sci.
106:883–890. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sinn M, Bahra M, Liersch T, Gellert K,
Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau
BM, et al: CONKO-005: Adjuvant chemotherapy with gemcitabine plus
erlotinib versus gemcitabine alone in patients after R0 resection
of pancreatic cancer: A multicenter randomized phase III trial. J
Clin Oncol. 35:3330–3337. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li
L, Wang F, Hao Y, Li C and Chi Y: Safety, pharmacokinetics, and
antitumor properties of anlotinib, an oral multi-target tyrosine
kinase inhibitor, in patients with advanced refractory solid
tumors. J Hematol Oncol. 9(105)2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Han B, Li K, Wang Q, Zhang L, Shi J, Wang
Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a
third-line or further treatment on overall survival of patients
with advanced non-small cell lung cancer: The ALTER 0303 phase 3
randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wu H, Huang N, Zhao C, Hu X, Da L, Huang
W, Shen Y, Xiong F and Zhang C: Anlotinib plus
nab-paclitaxel/gemcitabine as first-line treatment prolongs
survival in patients with unresectable or metastatic pancreatic
adenocarcinoma: A retrospective cohort. Ann Transl Med.
10(294)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Shen G, Zheng F, Ren D, Du F, Dong Q, Wang
Z, Zhao F, Ahmad R and Zhao J: Anlotinib: A novel multi-targeting
tyrosine kinase inhibitor in clinical development. J Hematol Oncol.
11(120)2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Yang L, Zhou X, Sun J, Lei Q, Wang Q, Pan
D, Ding M and Ding Y: Reactive oxygen species mediate
anlotinib-induced apoptosis via activation of endoplasmic reticulum
stress in pancreatic cancer. Cell Death Dis. 11(766)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhang X, Liu Y, Zhang Z, Tan J, Zhang J,
Ou H, Li J and Song Z: Multi-omics analysis of anlotinib in
pancreatic cancer and development of an anlotinib-related
prognostic signature. Front Cell Dev Biol. 9(649265)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Timmer FEF, Geboers B, Nieuwenhuizen S,
Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP,
Bruynzeel AME, Streppel MM, et al: Pancreatic cancer and
immunotherapy: A clinical overview. Cancers (Basel).
13(4138)2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhang F, Wang Y, Yang F, Zhang Y, Jiang M
and Zhang X: The efficacy and safety of PD-1 inhibitors combined
with nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus
gemcitabine in the first-line treatment of advanced pancreatic
cancer: A retrospective monocentric study. Cancer Manag Res.
14:535–546. 2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Shui L, Cheng K, Li X, Shui P, Zhou X, Li
J, Yi C and Cao D: Study protocol for an open-label, single-arm,
phase Ib/II study of combination of toripalimab, nab-paclitaxel,
and gemcitabine as the first-line treatment for patients with
unresectable pancreatic ductal adenocarcinoma. BMC Cancer.
20(636)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Liu Q, Zhao G, Zhang X, Jiang N, Zhao Z,
Wang Y, Xu S, Zhu L, Lau WY, Dai G and Liu R: Nab-paclitaxel plus
S-1 with or without PD-1 inhibitor in pancreatic ductal
adenocarcinoma with only hepatic metastases: A retrospective cohort
study. Langenbecks Arch Surg. 407:633–643. 2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly
EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, et
al: Sotigalimab and/or nivolumab with chemotherapy in first-line
metastatic pancreatic cancer: Clinical and immunologic analyses
from the randomized phase 2 PRINCE trial. Nat Med. 28:1167–1177.
2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Feng M, Xiong G, Cao Z, Yang G, Zheng S,
Song X, You L, Zheng L, Zhang T and Zhao Y: PD-1/PD-L1 and
immunotherapy for pancreatic cancer. Cancer Lett. 407:57–65.
2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Royal RE, Levy C, Turner K, Mathur A,
Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I and
Rosenberg SA: Phase 2 trial of single agent ipilimumab
(anti-CTLA-4) for locally advanced or metastatic pancreatic
adenocarcinoma. J Immunother. 33:828–833. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
O'Reilly EM, Oh DY, Dhani N, Renouf DJ,
Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, et al:
Durvalumab with or without tremelimumab for patients with
metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized
clinical trial. JAMA Oncol. 5:1431–1438. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: Pembrolizumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301.
2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Motzer RJ, Penkov K, Haanen J, Rini B,
Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S,
Uemura M, et al: Avelumab plus axitinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115.
2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Makker V, Rasco D, Vogelzang NJ, Brose MS,
Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, et
al: Lenvatinib plus pembrolizumab in patients with advanced
endometrial cancer: An interim analysis of a multicentre,
open-label, single-arm, phase 2 trial. Lancet Oncol. 20:711–718.
2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Li SQ, Yang Y and Ye LS: Angiogenesis and
immune checkpoint dual blockade: Opportunities and challenges for
hepatocellular carcinoma therapy. World J Gastroenterol.
28:6034–6044. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Fogelman DR, Wolff RA, Kopetz S, Javle M,
Bradley C, Mok I, Cabanillas F and Abbruzzese JL: Evidence for the
efficacy of iniparib, a PARP-1 inhibitor, in BRCA2-associated
pancreatic cancer. Anticancer Res. 31:1417–1420. 2011.PubMed/NCBI
|
|
58
|
Kaufman B, Shapira-Frommer R, Schmutzler
RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G,
Stemmer SM, Hubert A, et al: Olaparib monotherapy in patients with
advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol.
33:244–250. 2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Sehdev A, Gbolahan O, Hancock BA, Stanley
M, Shahda S, Wan J, Wu HH, Radovich M and O'Neil BH: Germline and
somatic DNA damage repair gene mutations and overall survival in
metastatic pancreatic adenocarcinoma patients treated with
FOLFIRINOX. Clin Cancer Res. 24:6204–6211. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Fumet JD, Limagne E, Thibaudin M, Truntzer
C, Bertaut A, Rederstorff E and Ghiringhelli F: Precision medicine
phase II study evaluating the efficacy of a double immunotherapy by
durvalumab and tremelimumab combined with olaparib in patients with
solid cancers and carriers of homologous recombination repair genes
mutation in response or stable after olaparib treatment. BMC
Cancer. 20(748)2020.PubMed/NCBI View Article : Google Scholar
|
